Document is current
Any future updates will be listed below
-
Authors
Kim, Hyun J. https://orcid.org/0000-0001-7986-7798
Weber, Jeremy M.
Neely, Megan L. https://orcid.org/0000-0002-0101-1081
Case, Amy Hajari
Jbeli, Aiham H.
Li, Peide
Olson, Amy L. https://orcid.org/0000-0002-5368-0412
Snyder, Laurie D. https://orcid.org/0000-0002-5962-2184
,
Baker, Albert
Beegle, Scott
Belperio, John A.
Condos, Rany
Cordova, Francis
Southern, Brian
Dilling, Daniel
Fitzgerald, John
Flaherty, Kevin R.
Gibson, Kevin
Gulati, Mridu
Guntupalli, Kalpalatha
Gupta, Nishant
Hotchkin, David
Huie, Tristan J.
Kaner, Robert J.
Lancaster, Lisa H.
Lasky, Joseph A.
Lee, Doug
Liesching, Timothy
Lipchik, Randolph
Lobo, Jason
Luckhardt, Tracy R.
Mageto, Yolanda
Kokoszynska, Marta
Morrison, Lake
Namen, Andrew
Oldham, Justin M.
Paul, Tessy
Zhang, David
Porteous, Mary
Raj, Rishi
Ramaswamy, Murali
Russell, Tonya
Sachs, Paul
Safdar, Zeenat
Shafazand, Shirin
Siddiqi, Ather
Fowler, Reginald
Strek, Mary E.
Rivas-Perez, Hiram
Tabak, Jeremy
Walia, Rajat
Whelan, Timothy P. M.
-
Funding
Funding for this research was provided by:
The IPF-PRO/ILD-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc and run in collaboration with the Duke Clinical Research Institute and enrolling centres.
- License Information
-
More Information
Article History
Received: 2 October 2024
Accepted: 26 February 2025
First Online: 9 March 2025
Declarations
:
: HJK is a principal investigator at a site in the IPF-PRO/ILD-PRO Registry. HJK has received research support from Boehringer Ingelheim, FibroGen, Galapagos, the National Institutes of Health, Roche/Genentech, United Therapeutics. JMW, MLN and LDS are employees of the Duke Clinical Research Institute, which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc to run the IPF-PRO/ILD-PRO Registry. JLT also reports grants from AstraZeneca and CareDx and participation in advisory boards for Altavant, Avalyn, Natera, Sanofi, Theravance. AHC is a principal investigator at a site in the IPF-PRO/ILD-PRO Registry. AHC has received research support from Boehringer Ingelheim, Roche/Genentech, United Therapeutics, FibroGen, Veracyte, Galapagos, Pilant, Kadmon, Bristol Myers Squibb, Bellerophon, Pulmonary Fibrosis Foundation (PFF), Galecto; consulting fees from Veracyte; speaker fees from Boehringer Ingelheim, Genentech, The France Foundation, Paradigm Medical; medical writing support from Boehringer Ingelheim, Veracyte, United Therapeutics; and has acted as a medical advisor to the PFF. AHJ has no disclosures. PL and ALO are employees of Boehringer Ingelheim Pharmaceuticals, Inc.
: The study was approved by the Duke University Institutional Review Board (Pro00046131). The protocol was approved by the relevant Institutional Review Boards and/or local Independent Ethics Committees prior to patient enrollment at every site (listed in the Acknowledgements).
: All patients provided written consent prior to entering the registry.
: Not applicable.
